Citations

Clear

633 citation(s) found for "Reid, J".

White Matter Tract Vulnerability to Amyloid Pathology on the Alzheimer’s Disease Continuum
Chandio, Bramsh Q. , Weiner, Michael W. , Garyfallidis, Eleftherios , Jahanshad, Neda , Braskie, Meredith N. , Nir, Talia M. , Villalón‐Reina, Julio E. , Thomopoulos, Sophia I. , Feng, Yixue , Reid, Robert I. , Jack, Clifford R. , O’Bryant, Sid E. , Thompson, Paul M. , Initiative, the Alzheimer’s Disease Neuroimaging, Team, the Health and Aging Brain Study (HABS-HD) Study

Mayo Clinic

2025 21st International Symposium on Biomedical Image Processing and Analysis (SIPAIM) | December 18, 2025 | Volume: No volume available | Issue: No issue available | Pages: 1-5

10.1109/sipaim67325.2025.11283325 Get It

DTI versus NODDI White Matter Microstructural Biomarkers of Alzheimer’s Disease
Liou, Kenny, Yoo, Hannah, Shuai, Yuhan , Chehrzadeh, Sasha, Borowski, Bret, Jahanshad, Neda , Liou, Kenny , Thomopoulos, Sophia I. , Yoo, Hannah, Arani, Arvin , Reid, Robert I. , Jack, Clifford R. , Weiner, Michael W. , Thompson, Paul M. , Nir, Talia M. , Initiative, Alzheimer’s Disease Neuroimaging

Mayo Clinic

2025 21st International Symposium on Biomedical Image Processing and Analysis (SIPAIM) | December 18, 2025 | Volume: No volume available | Issue: No issue available | Pages: 1-4

10.1109/sipaim67325.2025.11283294 Get It

PD-1–based combinations before autologous transplant are associated with improved outcomes in classical Hodgkin lymphoma
Desai, Sanjal H. , Moskowitz, Alison J. , Pederson, Levi , Geyer, Susan, Ganesan, Nivetha , Chang, Tiffany , Othman, Tamer , Falade, Ayo , Ng, Lay She , Baron, Margaret Kelsey , Ong, Shin Yeu , Yoon, Kevin, Ansell, Stephen M. , Armand, Philippe , Iyengar, Siddharth , Micallef, Ivana N. , Herrera, Alex F. , Pederson, Levi D , Chang, Tiffany , Othman, Tamer , Falade, Ayo S , Shah, Gunjan L , Sumransub, Nuttavut , Baron, Kelsey , Ong, Shin Yeu , Micallef, Ivana, Stuver, Robert , Herrera, Alex F , Mei, Matthew , Desai, Sanjal , Merryman, Reid W. , Shah, Harsh, Shah, Gunjan L. , Durani, Urshila , Stuver, Robert , Mei, Matthew

Mayo Clinic

Blood | December 17, 2025 | Volume: 147 | Issue: 10 | Pages: 1125-1134

10.1182/blood.2025030151 | PMID 41405496 Get It

Abstract Combination therapy incorporating programmed cell death protein 1 (PD-1) blockade results in unprecedented response rates in both frontline and relapsed/refractory (R/R) classical Hodgkin lymphoma (cHL). Previous retrospective studies have suggested benefit for PD-1 blockade before autologous stem cell transplant (ASCT) but included few patients receiving PD-1 blockade with cytotoxic chemotherapy. To explore the impact of anti–PD-1 based salvage on outcomes for patients with R/R cHL, we retrospectively reviewed 1280 patients with R/R cHL who underwent ASCT from 2010 to 2022 at 6 transplant centers, none of whom received PD-1 blockade as part of frontline therapy. Overall, 25% received a PD-1 inhibitor at any point before ASCT (10% in conjunction with chemotherapy), 28% received salvage brentuximab vedotin (BV) without PD-1 blockade, and the rest received salvage chemotherapy alone. Patients who received PD-1 inhibitors at any point before ASCT had a significantly higher 2-year progression-free survival than those who received BV without PD-1 inhibitors or patients receiving chemotherapy alone (88.2%, 70.2%, and 67.4%, respectively; P< .0001). When restricted to patients in complete response before ASCT, the benefit of PD-1 blockade remained significant. PD-1 blockade before ASCT is independently associated with superior post-ASCT outcomes and patients proceeding to ASCT should be treated with PD-1–based salvage.
Plasma cell identity escape drives resistance to anti-BCMA T-cell–redirecting therapy in multiple myeloma
Freeman, Ciara L. , Garcés, Juan-José, Lee, Holly , Papadimitriou, Marios , Silva, Ariosto Siqueira , Füller, Etta Rozen , Agius, Phaedra , Hansen, Doris K., Zhao, Xiaohong , Meads, Mark B. , Teer, Jamie K. , Hagner, Patrick R. , Alsina, Melissa , Ramasubramanian, Anusuya , Smith, Eric L. , Mailankody, Sham , Chesi, Marta, Hamadeh, Issam S. , Shain, Kenneth H. , Ilundain, Marta Larrayoz , Durante, Michael , Sharik, Meaghen E. , Du, Megan T. , Hagner, Patrick, Bergsagel, P. Leif , Landgren, C Ola , Maura, Francesco , Maclachlan, Kylee , Larráyoz, Marta , Ziccheddu, Bachisio , Meermeier, Erin W. , Garcés, Juan‐José , Durante, Michael , Firestone, Ross , Menges, Meghan A. , Reid, Kayla M. , Diamond, Benjamin , Sudalagunta, Praneeth Reddy , Leblay, Noémie , Ahn, Sungwoo , Fuller, Ethan, Briercheck, Edward L. , Hansen, Doris K. , Song, Xiaofei , Jelı́nek, Tomáš , Baz, Rachid , Smith, Eric, Giralt, Sergio , Bergsagel, P. Leif , Neri, Paola , Chesi, Marta , Martinez‐Climent, José A. , Locke, Frederick L. , Bahlis, Nizar Jacques , Landgren, Ola , Usmani, Saad Z.

Mayo Clinic

No container title available | December 15, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2025.12.08.692978 | PMID 41415462 Get It

ABSTRACT Chimeric antigen receptor T-cell (CART) and T-cell engager (TCE) therapies targeting B-cell maturation antigen (BCMA) are transforming the treatment landscape for relapsed multiple myeloma (MM). However, despite impressive initial response rates, most patients eventually relapse. To investigate this unmet medical need, we applied whole-genome sequencing (WGS) to MM cells from cohorts of 102 relapsed patients treated with anti-BCMA CART and TCE therapies. Several genomic alterations were associated with clinical outcomes, particularly primary refractoriness, including high genomic complexity and mutations in genes regulating plasma cell identity, which predicted resistance to therapy. Single-cell RNA sequencing further revealed that MM cells from refractory patients exhibited high proliferation signatures and reduced expression of TNFRSF17 (encoding BCMA), while were less enriched for plasma cell–associated transcriptional programs, a phenomenon we term “plasma cell identity escape.” This profile was strongly associated with immune dysregulation of CD8 T cells including increased activation and exhaustion. This evolution of MM toward a more proliferative and lineage-divergent state, refractory to the anti-BCMA T-cell redirecting therapies, was functionally validated in preclinical MM mouse models. Collectively, our results comprehensively define the cellular and molecular mechanisms underlying primary resistance to anti-BCMA therapies.
Benefit of rituximab maintenance after first-line bendamustine-rituximab in patients with mantle cell lymphoma
Wang, Yucai , Hwang, Steven R. , Villa, Diego , Kugathasan, Laveniya , Kumar, Anita , Joseph, Ashlee , Brooks, Taylor , Hill, Brian T. , Bond, David A. , Maddocks, Kami J. , Nizamuddin, Imran , Danilov, Alexey V. , Argao, Christine, Ruan, Jia , Khan, Nazneen B., Ouchveridze, Evguenia, Mou, Eric , Pongas, Georgios , Lossos, Izidore S. , Harris, Zoey I., Young, Philip, Greenwell, Irl Brian , Gerber, Drew G. , Wang, Michael , Narkhede, Mayur , Stack, Anthony , Messmer, Marcus , Moyo, Tamara K. , Anna, Jacob, Stanisic, Alexander , Cohen, Jonathon B. , Hwang, Steven R , Villa, Diego , Kumar, Anita , Joseph, Ashlee , Brooks, Taylor R , Bond, David A , Kahl, Brad S , Ryan, Christine E , Grover, Natalie S , Tun, Aung M , Mou, Eric , Lossos, Izidore S , Moustafa, Muhamad Alhaj , Pophali, Priyanka , Gerber, Drew , Jain, Preetesh , Wang, Michael L , Narkhede, Mayur S , Mehta, Amitkumar , Stack, Anthony C , Bhansali, Rahul S , Barta, Stefan K , Ghosh, Nilanjan , Kamdar, Manali , Stanisic, Alexander V , Karmali, Reem , Maurer, Matthew , Cerhan, James R , Cohen, Jonathon B , Wang, Yucai , Larson, Melissa C. , Kahl, Brad S. , Ryan, Christine E. , Merryman, Reid W. , Grover, Natalie S. , Ouchveridze, Evguenia, Tun, Aung M. , Ayyappan, Sabarish Ram , Muñoz, Javier , Portell, Craig A. , Baidoun, Firas , Moustafa, Muhamad Alhaj , Reagan, Patrick Michael , Banaszak, Lauren Gabriele , Pophali, Priyanka A. , Velayati, Arash , Jain, Preetesh , Mehta, Amitkumar , Bhansali, Rahul S. , Kamdar, Manali , Anna, Jacob, Karmali, Reem , Maurer, Matthew J. , Cerhan, James R. , Martin, Peter

Mayo Clinic

Blood Advances | December 11, 2025 | Volume: 10 | Issue: 4 | Pages: 1372-1380

10.1182/bloodadvances.2025018527 | PMID 41380101 Get It

Abstract The benefit of rituximab maintenance after first-line (1L) bendamustine-rituximab (BR) in patients with mantle cell lymphoma (MCL) remains uncertain, with inconsistent results from the phase 2 MAINTAIN trial and several retrospective studies. We conducted a large retrospective study at 27 US and Canadian academic centers to examine the benefit of rituximab maintenance after BR. A total of 911 patients received 1L BR between 2010 and 2020, and 703 had an objective response and no evidence of disease progression at the 3-month post-BR landmark. Among those, 394 (56%) received rituximab maintenance and 309 (44%) did not, with largely similar baseline patient and disease characteristics. In the landmark analysis, rituximab maintenance was associated with improved event-free survival (EFS; median, 49.9 vs 29.7 months; P< .001) as well as overall survival (OS; median, 109.5 vs 74.2 months; P< .001). The EFS and OS benefits were observed across most of the subgroups. EFS and OS differences were statistically significant in those who achieved a complete response to 1L BR (n = 590; median EFS, 62.7 vs 31.1 months [P< .001]; median OS, 136.1 vs 75.3 months [P< .001]), but the analysis among those who achieved a partial response to 1L BR was limited by the small sample size. These results provide additional evidence for the survival benefit of rituximab maintenance after BR in MCL and support its use in clinical trial design and routine practice.
Identifying candidates for outpatient administration of ciltacabtagene autoleucel (Cilta-cel) in relapsed-refractory multiple myeloma (RRMM)
Peres, Lauren C. , Shune, Leyla , Leitzinger, Christelle, Reid, Brett M. , Cassano, Raffaella Cassano , Kalariya, Nilesh, Gaballa, Mahmoud , Hunzeker, Zachary , Hosoya, Hitomi , Mikkilineni, Lekha , Gonzalez, Rebecca , Cahoon, Christopher, Sborov, Douglas W. , Bhurtel, Jenny , Purvey, Sneha , Ferreri, Christopher J. , Varga, Cindy , Voorhees, Peter M. , Goel, Utkarsh, Khouri, Jack , Afrough, Aimaz , Sannareddy, Aishwarya , Hassan, Hamza , Gordillo, Christian , Biran, Noa , Green, Kimberly , Zanwar, Saurabh , Costa, Luciano da Fontoura , Bal, Susan , Midha, Shonali , Alsina, Melissa , Shain, Kenneth H. , Kumar, Shaji , Patel, Krina, Sidana, Surbhi , Hansen, Doris, Davis, James A. , Sidana, Surbhi , Davis, James A , Hosoya, Hitomi , Dima, Danai , Colin, Christelle , Portuguese, Andrew J. , Banerjee, Rahul , Pasvolsky, Oren , Dillard, Christen , Grajales‐Cruz, Ariel , Puglianini, Omar Castañeda , Nishihori, Taiga , Wagner, Charlotte B , Kort, Jeries , Geer, Marcus , Atrash, Shebli , Goel, Utkarsh , Raza, Shahzad , Anwer, Faiz , Anderson, Larry D. , Herr, Megan M. , Reshef, Ran , Zolotov, Eli , Biran, Noa , Davis, James, Green, Kimberly, Lin, Yi , Costa, Luciano, Nadeem, Omar , Baz, Rachid , Locke, Frederick L. , Patel, Krina K. , Hansen, Doris K.

Mayo Clinic

Blood | December 5, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 4000-4000

10.1182/blood-2025-4000 Get It

Abstract Introduction: Cilta-cel is a BCMA-directed CAR T-cell therapy that has shown remarkable efficacy in patients with RRMM. As real-world (RW) experience with cilta-cel continues to expand, and with the recent FDA guidance reducing the recommended proximity to the CAR T center from four to two weeks post-infusion, there is growing interest in identifying patients at low risk for severe early complications who may be safely managed in the outpatient setting and potentially ‘discharged’ home earlier. Methods Data were collected from 769 patients with RRMM treated with cilta-cel at 15 institutions in the U.S. via the Multiple Myeloma Immunotherapy Consortium.Logistic regression was used to identify predictors of patients who could be managed in the outpatient setting (low-risk group). Based on expert consensus within the Consortium, low-risk patients were defined as: grade ≤1 CRS, no ICANS, and no IEC-HS. The remaining patients were categorized as high-risk. We evaluated baseline characteristics with missingness < 20% as predictors, including age, sex, race, and ethnicity, ECOG performance status (PS) at time of lymphodepletion (LD), extramedullary disease, bone marrow plasma cell (BMPC) percentage, high-risk cytogenetics, bridging therapy including response, penta-refractory status, number of prior lines of therapy, prior anti-BCMA therapy, baseline C-reactive protein (CRP), and baseline ferritin. The cohort was restricted to patients with complete data on all predictors (n=455) and split into a training and testing cohort (80/20 split, n=364/91). Bidirectional stepwise regression was used to build the predictive model using variables with significance of p<0.15 selected for entry. The best model was selected based on the AIC (Akaike Information Criterion) and a significance level of p<0.05. Results Among the 455 patients with complete data included in the final model, 290 (64%) were categorized as low-risk and 165 (36%) as high-risk. Compared to the low-risk group, high-risk patients were more likely to have an ECOG PS ≥2 at time of LD (20% vs 9%, p<0.001), high-risk cytogenetics (47% vs 35%, p=0.009), and penta-refractory disease status (34% vs 24%, p=0.031). High-risk patients also had a higher median BMPC percentage (15% vs 5%, p<0.001), and higher baseline pre-LD CRP and ferritin. Overall response rates were high, at 95% vs 90% (p=0.047) for the low vs high risk groups, with complete response or better achieved in 73% vs 66% of patients, respectively (p=0.14). With a median follow-up of approximately 11 months, median progression-free survival was not reached (95% CI: 27-NA) in the low-risk group and 18.2 months (95% CI: 13.1-NA) in the high-risk group. In terms of safety, non-ICANS neurotoxicity (NINT) occurred less frequently in the low-risk group (6.6% vs 13%, p=0.015). Specifically, Parkinsonism was observed in 1.7% vs 6.1% (p=0.013), and cranial nerve palsy in 4.5% vs 5.5% (p=0.7), respectively. Non-relapse mortality (NRM) was lower in the low-risk group (4.2%) compared to the high-risk group (14%; p < 0.001). The most common causes of NRM in the low- and high-risk groups were acute toxicities (0% vs 36%, including CRS, IEC-HS, and ICANS), delayed toxicities (0% vs 8%, including colitis, NINT, and Parkinsonism), infections (50% vs 48%), and other unrelated causes (50% vs 8%). The best model to predict low-risk patients that could be managed in the outpatient settingincluded BMPC percentage and ECOG PS at LD. In the training cohort, patients with a higher pre-LD BMPC percentage and an ECOG PS ³2 were less likely to be in the low-risk group(OR per 1-unit change in BMPC percentage = 0.99, 95% CI=0.98-0.99, p<0.001 and OR for ECOG PS 2-4 = 0.38, 95% CI=0.20-0.72, p=0.003). The AUC for this model was 0.663 in the training cohort and 0.659 in the testing cohort. Conclusion In this large, multi-institutional cohort of patients with RRMM treated with cilta-cel, we identified clinical factors associated with lower risk for early severe toxicities, supporting outpatient administration and the potential for earlier discharge in selected patients, particularly those who are fit and have low disease burden. Our findings provide a practical framework to guide risk stratification and outpatient CAR T management strategies, particularly in light of evolving regulatory guidance and growing RW experience with cilta-cel.
Association between cilta-cel dose and efficacy and toxicity outcomes for patients with Relapsed/Refractory multiple myeloma (RRMM): A real-world analysis from the US multiple myeloma immunotherapy consortium
Jensen, Alexandria , Gordillo, Christian , Reid, Brett M. , Peres, Lauren C. , Gaballa, Mahmoud , Afrough, Aimaz , Ferreri, Christopher J. , Varga, Cindy , Rana, Masooma , Hosoya, Hitomi , Mikkilineni, Lekha , Hovanky, Vanna, Zanwar, Saurabh , Kalariya, Nilesh, Mikulski, Damian , Cahoon, Christopher, Avila, Gabriel De, Bhurtel, Jenny , Goel, Utkarsh , Sannareddy, Aishwarya , Cassano, Raffaella Cassano , Midha, Shonali , Davis, James A. , Gonzalez, Rebecca , Purvey, Sneha , Green, Kimberly M , Liu, Hien , Khouri, Jack , Bal, Susan , Freeman, Ciara L. , Shune, Leyla , Shain, Kenneth H. , Alsina, Melissa , Sborov, Douglas W. , Dahiya, Saurabh , Miklos, David B., Voorhees, Peter M. , Costa, Luciano da Fontoura , Biran, Noa , Kumar, Shaji , Patel, Krina K. , Sidana, Surbhi , Sidana, Surbhi , Davis, James A , Hosoya, Hitomi , Reshef, Ran , Dima, Danai , Banerjee, Rahul , Pasvolsky, Oren , Dillard, Christen , Atrash, Shebli , Portuguese, Andrew J. , Wagner, Charlotte B , Puglianini, Omar Castañeda , Zolotov, Eli , Grajales‐Cruz, Ariel , Kort, Jeries , Herr, Megan M. , Xie, Zhuoer , Hassan, Hamza , Geer, Marcus , Perna, Fabiana , Nishihori, Taiga , Raza, Shahzad , Anwer, Faiz , Nadeem, Omar , Baz, Rachid , Locke, Frederick L. , Miklos, David B. , Anderson, Larry D. , Lin, Yi , Hansen, Doris K.

Mayo Clinic

Blood | December 5, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 134-134

10.1182/blood-2025-134 Get It

Abstract Introduction: Ciltacabtagene autoleucel (cilta-cel) is a highly effective BCMA-redirected CAR T-cell therapy for RRMM. While the pivotal CARTITUDE-1 trial established a target dose of 0.75 x 10^6 CAR+ viable T-cells/kg, the approved cell dose is 0.5-1.0 x 10^6 and the optimal dosing strategy to balance efficacy and toxicity remains unclear. This question is of interest given that a dose-response association has been demonstrated for idecabtagene vicleucel (a related BCMA-directed CAR T product). It has also been hypothesized that lower doses of cilta-cel may be associated with reduced toxicity. This study aims to evaluate the association between cilta-cel dose and key efficacy and toxicity outcomes using a large, real-world dataset from the US Multiple Myeloma Immunotherapy Consortium. Methods: We conducted a multicenter, retrospective analysis of 751 RRMM patients treated with commercial cilta-cel across 15 US academic centers. The administered cilta-cel dose (million cells/kg) was categorized into four groups: low (<0.5), standard-low (0.5 to <0.6), standard (0.6 to <0.8), and standard-high (0.8 to 1.0). We compared incidence rates of cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), delayed neurotoxicity (DNT), and immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome (IEC-HS) across these dose categories using logistic regression. Best response rates and progression-free survival (PFS), estimated using the Kaplan-Meier method, were also compared, with differences assessed using the log-rank test for the latter. Results presented are derived from multivariable models adjusting for extramedullary disease, ECOG status, penta-refractory disease and receipt of bridging therapy. Results: Among 751 infused patients, the dose distribution was: <0.5 (n=33), 0.5 to <0.6 (n=131), 0.6 to <0.8 (n=550), and 0.8 to 1.0 (n=37). The four dose groups were well-balanced in terms of baseline patient and disease characteristics, including age, high-risk cytogenetics, and extramedullary disease, with the exception of t(14;16), which was more common in the standard-low and standard dose groups (p=0.006). There were no statistically significant differences in the rates of any grade CRS (p=0.11), any grade ICANS (p=0.84), grade ≥3 ICANS (p=0.36), duration of CRS (p=0.18) or ICANS (p=0.64), or IEC-HS (p=0.16) across the four dose categories. Time to onset of CRS was shorter for the standard-high dose compared to the low dose (6 days vs. 8 days; p=0.08). Importantly, there was no significant difference in the rate of DNT (3.0%, 9.2%, 8.8%, 5.4%; p=0.24). Similarly, there was no significant difference in overall response rates (97%, 96%, 96%, 88%; p=0.50) or complete response rates (75%, 65%, 75%, 66%; p=0.10) by dose. The median follow-up was 12.3 months (IQR: 6.9, 20.5). For patients who received a standard-low dose (0.5, 0.6), the median PFS was 17.5 (IQR: 13.5, NR) months. For the standard dose range of (0.6, 0.8), the median PFS was 28.7 (95% CI: 19.8, NR) months, while the median PFS for the standard-high dose (0.8, 1.0) was not reached. For the low dose range of <0.5, the median follow up was only 8.7 months, which did not allow reliable estimation of the median PFS. While the overall difference in PFS among the groups did not reach statistical significance by the log rank test, there was a clear trend toward improved PFS with higher cell doses in the multivariable model, with outcomes clearly ordered in the same direction as the cell dose categories. A similar trend was also evident in the rates of 12-month PFS which showed an improvement with increasing dose (62% ,67%, 73%, 80%). Conclusions: In this large, real-world cohort of RRMM patients treated with cilta-cel, a lower cell dose was not associated with reduced incidence or severity of CRS, ICANS, DNT, or IEC-HS. Conversely, a dose-response correlation with PFS was observed, with higher doses trending toward longer median and 12-month PFS. It remains unknown if a lower cell dose in the commercial setting reflects poor T cell quality, yet these findings suggest that dose reduction of cilta-cel may not be an effective strategy to mitigate toxicities and might be associated with a trend toward lower efficacy. Therefore, the standard target dose should be utilized to maximize patient outcomes and further prospective dose exploration is warranted.
Optimal ferritin threshold to diagnose immune effector cell-associated hemophagocytic syndrome (IEC-HS) following CAR-T therapy in relapsed/refractory multiple myeloma (RRMM)
Lee, Jerry , Jensen, Alexandria , Hosoya, Hitomi , Zanwar, Saurabh , Gaballa, Mahmoud , Khouri, Jack , Goel, Utkarsh , Hovanky, Vanna, Rana, Masooma , Green, Kimberly M , Afrough, Aimaz , Anderson, Larry , Biran, Noa , Shune, Leyla , Ferreri, Christopher, Varga, Cindy , Voorhees, Peter M. , Sborov, Douglas W. , Freeman, Ciara L. , Cassano, Raffaella Cassano , Salva, Karla Feliciano, Peres, Lauren C. , Reid, Brett M. , Patel, Krina, Frank, Matthew J. , Hansen, Doris, Sidana, Surbhi , Shah, Nirali, Mikkilineni, Lekha , Davis, James A. , Sidana, Surbhi , Davis, James A , Hosoya, Hitomi , Pasvolsky, Oren , Dillard, Christen , Raza, Shahzad , Anwer, Faiz , Davis, James, Zolotov, Eli , Herr, Megan M. , Hassan, Hamza , Kort, Jeries , Atrash, Shebli , Fortuna, Gliceida Galarza , Julian, Kelley , Dima, Danai , Banerjee, Rahul , Portuguese, Andrew J. , Locke, Frederick L. , Puglianini, Omar Castañeda , Grajales‐Cruz, Ariel , Jain, Michael D. , Patel, Krina K. , Lin, Yi , Hansen, Doris K. , Shah, Nirali N

Mayo Clinic

Blood | December 5, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 717-717

10.1182/blood-2025-717 Get It

Abstract Background: IEC-HS is a potentially life-threatening complication following CAR-T therapy in RRMM. Reliable diagnostic biomarkers are needed to help expeditiously identify cases to initiate prompt treatment and supportive care. Serum ferritin, a routinely available laboratory parameter, is commonly elevated in IEC-HS and has been used to identify cases. However, ferritin can also be elevated in cytokine release syndrome (CRS) or secondary to baseline tumor-related inflammation. The optimal diagnostic threshold for post-CAR-T ferritin in IEC-HS in RRMM has not been previously established. Methods: This study used data from 15 centers within the US Multiple Myeloma Immunotherapy Consortium to identify the optimal post-CAR-T ferritin threshold to distinguish RRMM patients (pts) with and without a diagnosis of IEC-HS. Receiver operating characteristic (ROC) analysis was used to determine the optimal threshold based on Youden's Index. The performance of the threshold was evaluated overall and stratified by CAR-T product (cilta-cel, ide-cel). Additional analyses included the temporal relationship of peak ferritin and IEC-HS diagnosis, the evaluation of IEC-HS criteria according to ferritin levels, comparison of IEC-HS criteria co-occurrence, and comprehensive baseline characteristic comparisons across ferritin strata. Results: Of 1502 RRMM CAR-T recipients (ide-cel, n=712; cilta-cel, n=790), 74 patients (4.9%) had a provider-determined diagnosis of IEC-HS. A post-CAR-T ferritin threshold of 7470 ng/mL was identified as optimal for distinguishing pts with and without IEC-HS (AUC 0.938). Sensitivity (0.904) and specificity (0.934) were both very high, indicating high discriminatory ability. Stratified ROC analyses showed near-identical optimal thresholds for cilta-cel (7450 ng/mL; sensitivity 0.885, specificity 0.936, AUC 0.94) and ide-cel (7470 ng/mL; sensitivity 0.952, specificity 0.933, AUC 0.95), indicating minimal impact of CAR-T product on ferritin's prognostic utility. Baseline pt characteristics (N=1,413) differed significantly by ferritin threshold. Pts above the ferritin threshold of 7470 (N=154) were younger (median 64 vs 67 years; p=0.004), more frequently male (65% vs 56%; p=0.043), had higher baseline ferritin (1,300 vs 187; p<0.001), higher ECOG at apheresis (p=0.001), more likely penta-refractory (p=0.016), had higher baseline bone marrow plasma cell burden (p<0.001), and had higher R-ISS scores (p<0.001). Evaluation of IEC-HS criteria (Hines et al, TCT 2023) demonstrated significantly higher rates of laboratory and clinical criteria, including hepatic transaminase elevation (43% vs 15%), hypofibrinogenemia (53% vs 0%), cytopenias (95% vs 81%), hypertriglyceridemia (43% vs 8%), ICANS (52% vs 23%), renal insufficiency (20% vs 0%), and soluble IL-2 receptor elevations (47% vs 4%), in pts with ferritin >7500 ng/mL compared to those with lower ferritin. Heatmap visualization revealed distinct patterns of co-occurring criteria in high- and low-ferritin groups. Assessment of the timing of peak ferritin and IEC-HS diagnosis among IEC-HS cases revealed a median difference of 0 days (IQR: -1, 0), suggesting simultaneous occurrence. Median time to max ferritin was 9 days (IQR 8,12) in IEC-HS pts compared to 8 days (IQR 5,10) in non-IEC-HS pts (Wilcoxon p<0.05). Conclusions: In this analysis of over 1500 patients, a post-CAR-T ferritin level of 7500 ng/mL robustly identifies RRMM pts with IEC-HS following either cilta-cel or ide-cel. Pts exceeding this threshold demonstrate marked enrichment in IEC-HS diagnostic criteria and significant differences in baseline characteristics, warranting further study of the role of ferritin in IEC-HS diagnosis and early intervention.
Real-world outcomes of immune effector cell-associated hemophagocytic syndrome (IEC-HS) following ide-cel and cilta-cel therapy in relapsed/refractory multiple myeloma
Lee, Jerry , Jensen, Alexandria , Hosoya, Hitomi , Afrough, Aimaz , Zanwar, Saurabh , Gaballa, Mahmoud , Khouri, Jack , Goel, Utkarsh , Hovanky, Vanna, Rana, Masooma , Green, Kimberly M , Anderson, Larry , Biran, Noa , Shune, Leyla , Ferreri, Christopher, Varga, Cindy , Voorhees, Peter M. , Sborov, Douglas W. , Freeman, Ciara L. , Salva, Karla Feliciano, Cassano, Raffaella Cassano , Peres, Lauren C. , Reid, Brett M. , Patel, Krina, Frank, Matthew J. , Hansen, Doris, Sidana, Surbhi , Shah, Nirali, Mikkilineni, Lekha , Davis, James A. , Sidana, Surbhi , Davis, James A , Hosoya, Hitomi , Pasvolsky, Oren , Dillard, Christen , Raza, Shahzad , Anwer, Faiz , Davis, James P. , Zolotov, Eli , Herr, Megan M. , Hassan, Hamza , Kort, Jeries , Atrash, Shebli , Fortuna, Gliceida Galarza , Julian, Kelley , Dima, Danai , Portuguese, Andrew J. , Banerjee, Rahul , Puglianini, Omar Castañeda , Grajales‐Cruz, Ariel , Jain, Michael D. , Patel, Krina K. , Locke, Frederick L. , Lin, Yi , Hansen, Doris K. , Shah, Nirali N

Mayo Clinic

Blood | December 5, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 719-719

10.1182/blood-2025-719 Get It

Abstract Introduction: IEC-HS is an emerging and potentially life-threatening complication in multiple myeloma (MM) patients (pts) treated with CAR-T therapies. We conducted a retrospective, multi-institutional analysis to define the features and outcomes of IEC-HS after ide-cel or cilta-cel in the real-world setting. Methods: This study used data from 15 centers within the US Multiple Myeloma Immunotherapy Consortium for patients with relapsed/refractory MM (RRMM) who received commercial cilta-cel or ide-cel. IEC-HS was defined by each center based on diagnostic criteria (Hines et al, TCT 2023). Kaplan-Meier and multivariable Cox models were used for time-to-event outcomes while logistic regression was used for categorical outcomes. Results: Of 1502 RRMM pts who received either ide-cel (n=712) or cilta-cel (n=790), 74 patients (4.9%) had a provider-determined diagnosis of IEC-HS. Product-specific incidences were 2.9% for ide-cel and 6.7% for cilta-cel. The median time from CAR-T infusion to IEC-HS onset was 9.5 days (range 2-37 days). IEC-HS-related clinical findings (Hines et al, 2024) included cytopenias (95%), elevated soluble IL-2R levels (79%), fever (76%), elevated LDH (71%, median 1,800 U/L), hypofibrinogenemia (70%), hypertriglyceridemia (65%), ICANS (63%), hepatic transaminase elevation (56%), pulmonary involvement (46%), renal insufficiency (29%), hyperbilirubinemia (22%), and hemophagocytosis in bone marrow (6%). The median interval from peak CRS to IEC-HS onset was 4 days (IQR 1–6). Some variables, such as splenomegaly and coagulopathy, were not systematically collected. Nearly all pts received pharmacologic intervention: corticosteroids (94%, n=59), anakinra (76%, n=48), tocilizumab (71%, n=45), emapalumab (13%, n=8), ruxolitinib (16%, n=10), or etoposide (3%, n=2). Only one pt (2%) did not receive any IEC-HS therapy. Among those evaluable for outcomes, 58% (n=35) improved, 12% (n=7) developed further CAR-T-related complications (e.g., recurrent IEC-HS, delayed neurotoxicity), and 30% (n=18) had no therapeutic response and died. Compared to non-IEC-HS pts (n=1,428), those with IEC-HS were younger (median age 63 vs 66), male (61% vs 57%), and more frequently received cilta-cel (72% vs 52%, all p<0.01). They had higher rates of triple-class (81%) and penta-refractory (43%) disease, greater pre-treatment bone marrow plasma cell burden (40% vs 6%), and higher baseline ferritin (1058 vs 208 ng/mL). Prior autologous SCT was less common, and advanced R-ISS stage was more prevalent. IEC-HS was associated with dramatically worse PFS and OS: with cilta-cel, median PFS was 6.5 months (mo) with IEC-HS (vs 33.1 without); for ide-cel, 8.9 vs 11.4 mo. Median OS for cilta-cel IEC-HS pts was 9.6 mo (not reached in non-IEC-HS pts); for ide-cel IEC-HS, 19.6 mo (vs 40.8 mo). Multivariable analysis confirmed IEC-HS as an independent predictor of shorter PFS (HR 1.88, 95% CI 1.29–2.74, p=0.0011) and OS (HR 2.30, 95% CI 1.39–3.83, p=0.0013). Notably, IEC-HS was not associated with lower response rates – either best CR (63.9% vs 64.0%, p=0.71) or ORR (91.8% vs 90.9%, p=0.97). Cilta-cel pts had a higher probability of achieving a deep (CR) response, regardless of IEC-HS status. Grade > 3 CRS occurred in 14% (n=3/21) of ide-cel and 15% (n=8/52) of cilta-cel IEC-HS pts, versus 2% (n=12/691) and 2% (n=13/737) in non-IEC-HS pts, respectively. Any-grade ICANS was observed in 67% (n=14/21) of ide-cel and 55% (n=29/52) of cilta-cel IEC-HS cases, compared to 26% (n=179/690) and 20% (n=148/738) in non-IEC-HS. Grade ≥3 ICANS occurred in 29% (n=6/21) of ide-cel and 26% (n=14/52) of cilta-cel IEC-HS cases, relative to 4% (n=25/690) and 4% (n=27/738) in pts without IEC-HS. Severe infections were also more common: 71% (n=15/21) of ide-cel and 53% (n=28/52) of cilta-cel IEC-HS pts experienced at least one infection, compared to 31% (n=214/691) and 29% (n=217/737) in non-IEC-HS groups. Conclusions: IEC-HS is an uncommon but severe and early complication after CAR T-cell therapy for RRMM. Despite similar ORRs with or without IEC-HS, IEC-HS was associated with significantly worse PFS and OS for both ide-cel and cilta-cel. These findings support the need for vigilant monitoring and potential preemptive treatment strategies to better manage this syndrome.
Safety and efficacy of BCMA directed CAR-T therapy in older patients (Aged ≥ 75) with relapsed or refractory multiple myeloma (RRMM)
Jensen, Alexandria , Rana, Masooma , Peres, Lauren C. , Shune, Leyla , Reid, Brett M. , Abdallah, Nadine , Hosoya, Hitomi , Mikkilineni, Lekha , Cassano, Raffaella Cassano , Khouri, Jack , Ferreri, Christopher J. , Afrough, Aimaz , Biran, Noa , Purvey, Sneha , Hovanky, Vanna, Sborov, Douglas W. , Green, Kimberly , Freeman, Ciara Louise , Varga, Cindy , Goel, Utkarsh, Gaballa, Mahmoud , Zanwar, Saurabh , Dahiya, Saurabh , Alsina, Melissa , Lin, Yi, Voorhees, Peter M. , Patel, Krina, Sidana, Surbhi , Davis, James A. , Sidana, Surbhi , Davis, James A , Hosoya, Hitomi , Velayati, Arash , Dima, Danai , Pasvolsky, Oren , Portuguese, Andrew J. , Banerjee, Rahul , Fortuna, Gliceida Galarza , Julian, Kelley , Green, Kimberly, McGuirk, Joseph P. , Zolotov, Eli , Geer, Marcus , Puglianini, Omar Castañeda , Goel, Utkarsh , Anwer, Faiz , Raza, Shahzad , Dillard, Christen , Miklos, David B. , Davis, James P. , Herr, Megan M. , Reshef, Ran , Anderson, Larry D. , Patel, Krina K. , Hansen, Doris K.

Mayo Clinic

Blood | December 5, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 6375-6375

10.1182/blood-2025-6375 Get It

Abstract Background: Real-world data suggest that safety and efficacy of ide-cel and cilta-cel mirror data from pivotal trials, yet older adults remain underrepresented. We report outcomes of the largest cohort of RRMM patients aged ≥75 years receiving CAR-T and compare them with propensity-matched younger patients. Methods: We retrospectively analyzed RRMM patients receiving standard-of-care BCMA CAR-T at 15 centers from the US Myeloma Immunotherapy Consortium between May 2021 and December 2024. Patients ≥ 75 years were 2:1 propensity-matched to patients < 75 based on CAR-T product, sex, performance status, extramedullary disease, baseline ferritin, penta-refractory status, bridging therapy, prior autologous SCT and lines of therapy. Continuous outcomes were analyzed with multivariable linear regression, binary outcomes with logistic regression, and time-to-event endpoints with Cox proportional-hazards models. We estimated average treatment effects via G-computation, using cluster-robust standard errors to account for the matched sets. Results: After 2:1 propensity matching, the cohort included 194 patients ≥ 75 years (cilta-cel: 64 and ide-cel: 130) and 388 patients < 75 years (cilta-cel: 128, ide-cel: 260). Median ages were 78 (range: 75-90) for the older cohort vs 65 (range: 35-74) for the younger cohort. The older cohort had a higher frequency of t(14;16) (9% vs. 3%, p = 0.005), lower baseline ferritin (151 vs. 196 ng/mL, P = 0.046), and lower likelihood of prior ASCT (57% vs. 71%, P = 0.001). Median prior lines of therapy were 5. Median follow-up time for ≥ 75 and < 75 groups for cilta-cel was 11.5 and 11 months and for ide-cel was 16 and 24.3 months, respectively. ORR did not differ amongst the older vs younger patients: cilta-cel (97% vs. 97%) and ide-cel (90% vs. 88%).For patients ≥ 75 years, median PFS with cilta-cel was 28.7 months (95% CI: 13.3–NR) and with ide-cel was 16.4 months (95% CI: 12.1–22.4). In patients < 75 years, median PFS was not reached for cilta-cel but was 11.5 months (95% CI: 9.6–12.7) for ide-cel, reflecting inferior PFS with ide-cel in the younger group (HR 0.4, 95% CI 0.3–0.6). On sensitivity analysis by Cox proportional hazards model, we did not observe any statistically significant differences in PFS in older vs younger patients receiving cilta-cel, although older patients paradoxically had better PFS with ide-cel compared to their matched younger cohort. In the cilta-cel cohort, HR for PFS for older vs younger patients was 1.48 (95% CI:0.77-2.84; p=0.2) and in the ide-cel cohort it was 0.7 (95% CI: 0.5, 0.98; p=0.04). Median OS was reached only in the < 75-year ide-cel cohort at 40 months (95% CI: 32.5–43.5). Rates of CRS were similar, with any-grade (grade ≥3) CRS seen in 74% vs 78% (0% vs. 0.8%) of cilta-cel recipients and 86% vs. 87% (3.1% vs. 1.5%) of ide-cel recipients in the older vs younger groups, respectively. ICANS rates were 21% vs. 20% for cilta-cel (p = 0.79) and 29% vs 20% for ide-cel (p = 0.07), with similar rates of grade ≥ 3 ICANS. In the cilta-cel cohort, Parkinsonian delayed neurotoxicity (DNT) occurred in 3/62 (4.8%) older patients and 6/128 (4.7%) younger patients. Similarly, other non-Parkinsonian DNT rates were similar across age groups, with 6.4% vs 5.5% in older vs younger cilta-cel cohort and 0% vs 1% in the older vs younger ide-cel cohort. Rates of IEC-HS, and infections were comparable across the cohorts. There was no difference in hospital length of stay and ICU admission rate between products within either age cohort. The overall non-relapse mortality (NRM) was 6.7% for patients ≥ 75 years and 6.2% in patients < 75 years. For cilta-cel, NRM in older vs younger cohort was 9.4% vs 4.7% (p= 0.96) and for ide-cel it was 5.4% vs 6.9%, respectively (p= 0.65). Conclusion: Appropriately selected older adults (≥75 years) receiving CAR-T therapy for RRMM can derive a similar efficacy benefit with CAR-T as a propensity-matched younger cohort, without any increased signal of toxicity including CRS, ICANS or delayed NT. NRM was numerically greater, but not statistically significant, in older adults receiving cilta-cel. Median PFS with cilta-cel and ide-cel in older adults were 28.7 months and 16.4 months with median OS not reached and 40 months, respectively. Older adults, ≥75 years old, should not be excluded from CAR-T therapy solely due to advanced age. Overall, cilta-cel was not associated with worsened toxicities in older adults and may offer better PFS.